Savara Inc
SVRAHealthcare|Biotechnology|USA
$6.03
-0.26 (-4.06%)
Tangible Book
$0.80
Earnings Power
$0.88
Clinical Trials (14)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06431776 Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP). | Autoimmune Pulmonary Alveolar Proteinosis | P3 | Recruiting | 5 | Open-label | Molgramostim |
| NCT04544293 Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | Autoimmune Pulmonary Alveolar Proteinosis | P3 | Active | 164 | RCT, Double-blind | Molgramostim, Placebo, Molgramostim Open-label |
| NCT01515007 Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3) | Non Cystic Fibrosis Bronchiectasis | P3 | Completed | 278 | RCT, Double-blind | Ciprofloxacin dispersion for inhalation, Placebo |
| NCT02104245 Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4) | Non Cystic Fibrosis Bronchiectasis | P3 | Completed | 304 | RCT, Double-blind | Ciprofloxacin dispersion for inhalation, Placebo |
| NCT03181932 AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis | MRSA, Cystic Fibrosis | P3 | Completed | 188 | RCT, Double-blind | Vancomycin inhalation powder, Placebo inhalation powder, Vancomycin inhalation powder |
| NCT03482752 Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis | Autoimmune Pulmonary Alveolar Proteinosis | P3 | Terminated | 60 | Open-label | Molgramostim |
| NCT01746095 Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients | Cystic Fibrosis | P2 | Completed | 87 | RCT, Double-blind | Vancomycin hydrochloride inhalation powder, Placebo inhalation powder |
| NCT03597347 Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection | Mycobacterium Infections, Nontuberculous, Cystic Fibrosis (CF) | P2 | Terminated | 14 | Open-label | Molgramostim nebulizer solution |
| NCT03421743 Pilot Trial of Inhaled Molgramostim in Non-tuberculous Mycobacterial (NTM) Infection | Mycobacterium Infections, Nontuberculous | P2 | Completed | 32 | Open-label | Inhaled molgramostim, Antimycobacterial regimen |
| NCT02702180 Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis | Autoimmune Pulmonary Alveolar Proteinosis | P2 | Completed | 139 | RCT, Double-blind | Molgramostim, Placebo |
| NCT02468908 Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects | Pulmonary Alveolar Proteinosis, Bronchiectasis | P1 | Completed | 42 | RCT, Double-blind | Molgramostim, Placebo |
| NCT01537666 Inhaled Vancomycin Tolerability, Safety and Pharmacokinetics | Healthy, Cystic Fibrosis | P1 | Completed | 25 | Open-label | AeroVanc, IV vancomycin hydrochloride |
| NCT06546098 Molgramostim Nebulizer Solution Expanded Access Program Protocol | Autoimmune Pulmonary Alveolar Proteinosis | AVAILABLE | — | — | Molgramostim nebulizer solution | |
| NCT01090908 Evaluation of Ciprofloxacin for Inhalation to Cystic Fibrosis Patients With P. Aeruginosa | Cystic Fibrosis | Withdrawn | — | — | Antibiotic |